DECRYPTION – In decline ten years ago, the Anglo-Swedish laboratory has completely revived. It is redoubling its ambitions and targeting a turnover of 80 billion euros by 2030.
In 2014, Pascal Soriot, the newly appointed boss of AstraZeneca, promised his shareholders that it would reach 40 billion euros in turnover in 2023. The Anglo-Swedish laboratory was then under threat of a takeover bid. to $117 billion from Pfizer.
Ten years later, AstraZeneca is in a completely different shape. “ We have been through a scary time. We were in decline, remembered Pascal Soriot, Tuesday morning, during a day dedicated to investors. But we managed to turn the company around, and we did it through science. » AstraZeneca exceeded 45 billion euros in turnover last year, while its capitalization has almost tripled in ten years. At 65, the pugnacious boss behind this turnaround is doubling down, and is now aiming for $80 billion in turnover by 2030. “ If everything went perfectly, (….) we could even go beyond »anticipates the director…
This article is reserved for subscribers. You have 83% left to discover.
Do you want to read more?
Unlock all items immediately.
Already subscribed? Log in
